Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HP501 sustained-release tablets in primary gout with hyperuricemia (phase 2/3)
CTR20240587Phase 3Completed
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of HP501 in idiopathic gout, hyperuricemia, sponsored by Haisco Pharmaceutical Group Co., Ltd.. Started Mar 2024; status: completed.
02
Drugs
HP501
03
Conditions
idiopathic gouthyperuricemia
Beyond the preview
Go deeper on CTR20240587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240587.